Metformin treatment beneficial for obese children, teens

Metformin treatment beneficial for obese children, teens
Obese children and adolescents treated with twice-daily metformin have significantly improved body mass index standard deviation scores, fasting glucose, and other metabolic risk factors, according to research published online Nov. 21 in the Journal of Clinical Endocrinology & Metabolism.

(HealthDay)—Obese children and adolescents treated with twice-daily metformin have significantly improved body mass index standard deviation scores (BMI-SDS), fasting glucose, and other metabolic risk factors, according to research published online Nov. 21 in the Journal of Clinical Endocrinology & Metabolism.

Deborah Kendall, M.D., of the Royal Manchester Children's Hospital in the United Kingdom, and colleagues conducted a prospective, randomized, double-blind, placebo-controlled trial involving 151 obese children and adolescents from six pediatric endocrine centers to evaluate the effect of metformin, given at a dose of 1 g each morning and 500 mg each evening. Seventy-four participants were allocated to metformin and 77 were assigned to placebo for six months.

At three months, the researchers found that metformin-treated children and adolescents had significantly improved levels, alanine aminotransferase (ALT) levels, and adiponectin to leptin ratios (ALR) compared with placebo-treated participants. At six months, there were significant changes in BMI-SDS in metformin-treated participants compared with those who received placebo.

"The MOCA [Metformin in and Adolescents] trial provides evidence that a short treatment course of metformin is clinically useful, safe, and well tolerated to halt further gain in adiposity and improve fasting glucose, ALT, and ALR," the authors write. "Metformin may also provide a stimulus for further lifestyle changes and is a useful adjunct to support lifestyle modification and potentially reduce long-term risk of cardiovascular disease and type 2 diabetes."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Imeglimin beneficial as add-on to metformin in T2DM

Dec 14, 2012

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, ...

Metformin may have dual effect in breast cancer

May 09, 2012

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects ...

Recommended for you

Nigeria death shows Ebola can spread by air travel

10 hours ago

(AP)—Nigerian health authorities raced to stop the spread of Ebola on Saturday after a man sick with one of the world's deadliest diseases brought it by plane to Lagos, Africa's largest city with 21 million ...

Trial in salmonella outbreak to start in Georgia

10 hours ago

(AP)—Three people accused of scheming to manufacture and ship salmonella-tainted peanuts that killed nine people and sickened more than 700 are set to go to trial this week in Georgia.

Remote tribe members enter another village, catch flu

18 hours ago

Advocates for indigenous tribes are worried over incidents last month when some members of one of the last uncontacted tribes in the Peru/Brazil region, across borders, left their home in Peru and entered ...

Nigeria on red alert after first Ebola death

Jul 26, 2014

Nigeria was on alert against the possible spread of Ebola on Saturday, a day after the first confirmed death from the virus in Lagos, Africa's biggest city and the country's financial capital.

User comments